Related Experiment Video

Updated: Dec 22, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

552

Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia

Sai Huang1, Zhi Huang2, Chao Ma1

  • 1Department of Hematology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.

Annals of Translational Medicine
|May 2, 2020
PubMed
Abstract

Insights

Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) is linked to poor outcomes in acute myeloid leukemia (AML). This study identifies ANP32A as a potential prognostic marker and therapeutic target for AML patients.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates histone acetylation and influences leukemogenesis in acute myeloid leukemia (AML).
  • The prognostic significance of ANP32A in AML has not been clearly established.

Purpose of the Study:

  • To investigate the prognostic value of ANP32A expression in cytogenetically normal AML (CN-AML).
  • To explore the functional roles of ANP32A in AML through multi-omics analysis.

Main Methods:

  • Analysis of ANP32A expression in two independent CN-AML cohorts.
  • Multivariable analysis and multi-omics approaches including gene expression, microRNA, and methylation profiling.

Main Results:

  • Overexpression of ANP32A correlated with unfavorable overall survival (OS) and event-free survival (EFS) in CN-AML patients.
  • ANP32A was validated as a high-risk factor in multivariable analysis and associated with specific molecular alterations, including oncogene/tumor suppressor dysregulation, altered metabolic and immune pathways, and aberrant methylation patterns.

Conclusions:

  • ANP32A serves as a novel and significant unfavorable prognosticator in AML.
  • ANP32A represents a potential therapeutic target for AML treatment.
Keywords:
Acidic leucine-rich nuclear phosphoprotein-32A (ANP32A)cytogenetically normal acute myeloid leukemia (CN-AML)expressionprognostic biomarker

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.3K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.5K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Regulation of Nuclear Protein Sorting01:45

Regulation of Nuclear Protein Sorting

Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...
3.1K